The company R.T. Mat., Replacement Therapy Materials, was formed on april 5th -2000 in Mechelen - Belgium. Its main task is the marketing and sales of 'Bioplant® Hard Tissue Replacement' or HTR® for all general dentistery and oral restaurative surgery applications in the whole of Europe . R.T. Mat® is one part of 3 mutual allied companies. It is the marketing pillar that leans on the research & development units and Bioplant inc USA. Additionally a close cooperation has grown with professors of the Rijksuniversiteit Gent en de IART, the International Academy for Replacement Therapy, for expertise and scientific support. R.T. Mat. also works closely together on other fields with Bioplant, Inc.-USA.

Important chronological facts - In 1986 , US Surgical corporation, Inc. purchased the assets of Medical Biological Sciences, Inc (MBS), a research and development company which developped HTR® . - In 1992 Bioplant acquired the exclusive right to market HTR® worldwide in the field of dentistery. - In April 2000 , R.T Mat., Replacement Therapy Materials, was established, exclusively for the marketing, sales and support of HTR® products on the European continent.

Specialisation in bone-regenerating materials Our main activity is importing and distributing bone regenerating materials for medical applications, and this in the whole of Europe. Our main headproduct is Bioplant - Hard Tissue Replacement or HTR®, a patented bone substitute used in dental and orthopedic applications. HTR® is unique among bone substitutes in that is bone conductive material (i.e.,a bone promotor that regenerates new bone ) We are convinced at R.T.Mat. that this product is of such high quality that it will perform its task for live.

Achievements Since its market introduction, Bioplant® HTR® has been succesfully used by dental practioners in over 350.000 documented procedures worldwide. Clinical studies of Bioplant Hard Tissue Replacement have been conducted at Mt. Sinai Hospital, Columbia University, the University of Tennessee, Batelle Laboratories, the Weizman Institute Tel Aviv, New York University, Loma Linda, UCLA, the University of Indiana. An impressive list of more than 270 scientific publications shows the unmatched succes of Bioplant® HTR® synthetic bone.regenerating material. This bibliographie is available on simple request. Numerous clinical studies about the use of Bioplant® HTR® on both human and animal tissues have been conducted and are available. In every clinical test, there has been no significant adverse effects or rejection of the material. Up until now not one complaint concerning undesired effects of Bioplant® HTR® with humans was formulated. Bioplant® HTR® has received Food and Drug Administration (FDA) 510 k approval for: Dental applications including Jawbone preservation, Implant dentistry, Ridge Augmentation and treatment of Periodontal Defects. Bioplant® HTR® and R.T. Mat also received the CE mark and the ISO 9002 certificate for marketing and sales on the European market.

Market Potential Bioplant® HTR® generated over $ 5 million in sales worldwide in 1997 in dental applications alone. In Belgium there is a potential market from over 450.000 interventions per year where Bioplant® HTR® can be applied. For the whole of Europe this market is X time bigger. Bioplant® HTR® is for the moment the leading synthetic bone regenerating material in the dentistery field. This is not something to be astonished about, Bioplant® HTR® compared to all other synthetic and half synthetic bone fillers, has the highest succes ratio. This became clear in more than 270 scientific publications throughout the world, during the last decade Recent problematic developments in the food chain, like the presence of dioxines, but especially the emerging of the terrifying mad cow disease (BSE) have lead to it that few people can still place their trust in materials from animal origin. 100% synthetic materials are the ones people prefer, given the choice Bioplant and R.T.Mat are now moving to develop new products supporting the use of HTR®, especially with the use of implants. New products enable to shorten quite considerably the treatment and healing times. Where there was earlier an average of about one year before end of treatment, this will be reduced in the nearby future till about one week! In addition this product shows a very favorable price-quality ratio. This most certainly when all the advantages, as well on short as on the long term are taken into consideration Bioplant HTR® has also more recently been discovered to have additional applications appropriate for the orthopedic, neurology, urology and cosmetic Surgery markets But, this isn't everything, R.T. Mat. also represents a revolutionary concept named Replacement Therapy™. This makes it possible, that as well on the short as on the long term, maximal benefit can be derived out of a given situation. This concept offers as well for practioners as for their patients very promising future perspectives. Push here for more information about this concept.

Our team The team that stands behind R.T. Mat. shares the same vision. We all want to: "introduce a gamma of products that are especially developped to prevent or to reconstruct the patient's dental problems. They also offer to the dentist the advantage to achieve results, without complicated procedures. As a result even more satisfied patients can be expected." The R.T.Mat. team consists out of: Marc De Win, CEO and B2B relations responsible, Herman Poppe, Director and product responsible Mario Osvald, EO, Market developement responsible our ever growing salesteam We always remain available to answer your questions. Just push on one of the names or send us an e-mail. You can also fax or phone to one of the numbers listed below.